# iRadimed Corporation (IRMD) Stock Analysis: A Look at Its 29% Upside Potential

- Link: https://www.directorstalkinterviews.com/iradimed-corporation-irmd-stock-analysis-a-look-at-its-29-upside-potential/4121259575
- Published: 2026-08-07T10:15:09+01:00
- Author: Madison Wilson

For investors seeking opportunities in the dynamic healthcare sector, iRadimed Corporation(
IRMD) presents an intriguing proposition. As a leading provider of MRI-compatible
medical devices, the company’s stock is currently trading at $91.21, with analysts
projecting a significant potential upside of 29.37%, based on an average target 
price of $118.00.

iRadimed, headquartered in Orlando, Florida, operates within the medical devices
industry, specializing in innovative MRI-compatible intravenous infusion pump systems
and patient monitoring solutions. Its robust product portfolio, including the MRidium
3870 and 3860+ infusion pump systems and the 3880 patient monitoring system, underscores
its commitment to advancing patient safety and care in MRI environments.

Despite its innovative edge, iRadimed’s current valuation metrics reveal some areas
that may warrant closer investor scrutiny. The company lacks a trailing P/E ratio,
PEG ratio, and other traditional valuation metrics like Price/Book and Price/Sales.
However, its Forward P/E stands at 37.85, suggesting expectations of earnings growth.
The company’s impressive Return on Equity (ROE) of 23.52% further supports this 
growth narrative, indicating efficient management and profitability.

Revenue growth at iRadimed is modest at 0.30%, but the company has demonstrated 
strong earnings per share (EPS) of 1.78. Moreover, its free cash flow of $16.2 million
highlights the company’s ability to generate cash, a crucial factor for sustaining
operations and funding future innovations.

Investors will note iRadimed’s commitment to returning value to shareholders, as
evidenced by its dividend yield of 0.87% and a reasonable payout ratio of 41.34%.
This balance between reinvestment in growth and providing shareholder returns is
often a sign of a well-managed company.

Technical indicators provide additional insights into iRadimed’s stock dynamics.
The current price slightly trails its 50-day and 200-day moving averages, suggesting
potential for momentum shifts. With an RSI of 67.40, the stock is nearing overbought
territory, which investors should monitor closely. The MACD and Signal Line readings
also indicate a bearish trend, though these could reverse with positive news or 
earnings surprises.

Analyst sentiment towards iRadimed is notably positive, with two analysts rating
it a “Buy” and none recommending a “Hold” or “Sell.” This confidence is reflected
in the bullish target price range of $116.00 to $120.00. For investors, this consensus
suggests a favorable outlook, driven by the company’s specialized niche and growth
prospects.

In summary, iRadimed Corporation offers a compelling investment case within the 
medical devices sector. With a strong product lineup, proven profitability, and 
a significant upside forecast, it represents a promising opportunity for growth-
oriented investors. However, as with any investment, potential investors should 
conduct their due diligence, considering both the market conditions and the company’s
unique position in the healthcare landscape.

Share on:
